A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Inclusion Criteria: * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 * International Metastatic RCC Database Consortium (IMDC) risk intermediate (score of 1 or 2) or poor (score of 3-6) * Measurable disease with at least one measurable lesion * Histologically confirmed ccRCC with or without sarcomatoid features * Negative for HIV, hepatitis B, or hepatitis C virus (HCV) Exclusion Criteria: * Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 90 days after the final dose of tiragolumab, 4 months after the final dose of tobemstomig (RO7249669) and pembrolizumab, or for 1 week after the final dose of axitinib, whichever occurs last * Inability to swallow a tablet or malabsorption syndrome * Prior treatment for localized and/or metastatic RCC with systemic RCC-directed therapy, including T-cell costimulating or immune checkpoint blockade therapies * Ongoing use or anticipated need for treatment with a strong CYP3A4/5 inhibitor or inducer * Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study * Uncontrolled or symptomatic hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * History of leptomeningeal disease * Uncontrolled tumor-related pain * Uncont…